Tetrandrine in the Treatment of Rheumatoid Arthritis

NCT ID: NCT05245448

Last Updated: 2022-02-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 240 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-22
• Study Completion Date: 2024-03-31

Brief Summary

The purpose of this study is to assess the efficacy and safety of tetrandrine, compared with placebo in 12 week or 24 week in RA patients with inadequate response to methotrexate.

Detailed Description

The investigators designed a randomized, double-blinded, placebo-controlled, multicenter study. Adults with active rheumatoid arthritis and inadequate response to methotrexate will be enrolled, meeting the 1987 revised American College of Rheumatology (ACR) or 2010 ACR & European alliance of associations for rheumatology (EULAR) classification criteria. Two hundred forty patients at 18 to 65 years of age will be enrolled in the study, and be randomly assigned (in a 1:1 ratio) to one of the two arms (group1: tetrandrine 40mg tid for 24 weeks or group 2: placebo two tablets tid for 12 weeks, and then 40mg tid for 12 weeks). Follow-up visits will occur on weeks 4, 12 and 24. The end points were 20% improvement in American College of Rheumatology criteria (ACR20) in 12 week.

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

tetrandrine

tetrandrine administered 40milligram (mg) orally thrice daily through Week 24.

Group Type: EXPERIMENTAL

Tetrandrine

Intervention Type: DRUG

Administered orally

placebo

Placebo administered orally thrice daily through Week 12. Starting at Week 12, participants were given tetrandrine 40 milligram (mg) orally thrice daily through Week 24.

Group Type: PLACEBO_COMPARATOR

Tetrandrine

Intervention Type: DRUG

Administered orally

Placebo

Intervention Type: DRUG

Administered orally

Interventions

Tetrandrine

Administered orally

Intervention Type: DRUG

Placebo

Administered orally

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 18-65 years old.
• fulfilled the 1987 revised American College of Rheumatology (ACR) or 2010 ACR/EULAR classification criteria for RA.
• DAS28-ESR>3.2.
• MTX 7.5-20mg/w for at least 12 weeks before screening and keep stable doses for at least 4 weeks.
• Prednisone (≤10mg/d) or equivalent dose is allowed. However, the dose should be stable for at least 4 weeks before screening and should not increase during follow-up. If glucocorticoids are not used before screening, short- and intermediate-acting glucocorticoids should have been stopped at least 1 week and long-acting glucocorticoids should have been stopped at least 2 weeks.

Exclusion Criteria

• Allergic to the drugs involved in the study, or allergic to more than two kinds of food or drugs or pollen.
• Meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA Class IV in the Screening Phase.
• Any history or complication of other autoimmune diseases other than Sjogren's syndrome or Hashimoto Thyroiditis.
• Current active infections.
• Tested positive for any of the following in the Screening Phase: HIV, hepatitis B virus surface antigen (HBs antigen), hepatitis B virus surface antibody (HBs antibody), hepatitis C virus antibody (HCV antibody), or history of AIDs.
• Females of childbearing or breastfeeding.
• Presence of any unstable cardiovascular disease (including congestive heart failure with NYHA class III or IV, unstable angina pectoris, history of myocardial infarction within one year), and the presence of conditions that can lead to QTc prolongation or arrhythmia.
• Presence of progressive, uncontrolled cerebrovascular disease, hematopoietic, endocrine (including diabetes), respiratory (including interstitial pneumonia and pulmonary fibrosis) and other serious diseases and psychiatric diseases, or the investigator believes that participation in the study would place the subject at unacceptable risk.
• History of malignancy.
• Laboratory tests during screening：i. WBC<3.5×109/L，PLT<90×109/L， Hb<90g/L; ii. ALT or AST>1.5ULN; iii. Scr>ULN.
• Use of iguratimod or disease-modifying antirheumatic drugs (DMARDs) other than MTX (such as leflunomide, sulfasalazine, hydroxychloroquine, D- penicillamine, azathioprine, cyclosporine, cyclophosphamide, Tripterygium, etc.) within 4 weeks before enrollment.
• Use of traditional Chinese medicines for rheumatoid arthritis within 4 weeks before enrollment.
• Use of b/tsDMARDs within 12 weeks.
• History of alcohol and drug abuse.
• The investigator or subinvestigator would compromise the participant's ability to safely complete the study.
• Participate in other clinical trial within 3 months prior to screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zhanguo Li

Role: PRINCIPAL_INVESTIGATOR

Department of Rheumatology and Immunology, Peking University People's Hospital

Locations

Peking University People's Hospital

Beijing, , China

Countries

China

Central Contacts

Ru Li, MD, PhD

Role: CONTACT

doctorliru123@163.com

+86 1861161621

Facility Contacts

Zhanguo Li, MD, PhD

Role: primary

li99@bjmu.edu.cn

+86 10 88324178

Other Identifiers

2021-Z-40

Identifier Type: -

Identifier Source: org_study_id